Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. - Wikidata - wikimedia - TriplyDB

Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.

Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.

http://www.wikidata.org/entity/Q38489561

about

Role of ABL family kinases in cancer: from leukaemia to solid tumours Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase.New frontiers in pediatric Allo-SCT.How I treat childhood CML.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.Pediatric chronic myeloid leukemia is a unique disease that requires a different approach Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia Chronic myeloid leukemia in India: The poster child of translational medicine needs help!Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India.Management of chronic myeloid leukemia in childhood.Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches.Therapeutic approaches to haematological malignancies in adolescents and young adults.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.Is there a role for allogeneic transplantation in chronic myeloid leukemia?Treatment setting, clinical trial enrollment, and subsequent outcomes among adolescents with cancer: a literature review.Growth failure and nutrition considerations in chronic childhood wasting diseases.Targeted approaches to childhood cancer: progress in drug discovery and development.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.The development of targeted new agents to improve the outcome for children with leukemia.Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells.Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents.Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.Treatment of chronic phase chronic myeloid leukemia with imatinib.DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia.Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib.Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.Pharmacology and pharmacokinetics of imatinib in pediatric patients.Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib.Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.Optimal management for pediatric chronic myeloid leukemia.

P2860

Q28396643-22972693-F907-4012-9E44-43CAA27CCF62 Q33401360-A6728BEB-25F0-4874-97E2-F6BB07F5FE58 Q34538899-777130F7-DA04-4D92-8A9B-D387DAC09392 Q35628739-A3596752-3B7B-4913-88B3-3970C512F6FA Q35802202-9416A99C-88AE-4FB2-8847-35E4C3A9A0A7 Q36364850-F30E638B-2857-4B32-851E-86A558B33925 Q36577661-9E1CFAEF-4263-4706-8F15-65FEB49EEBE5 Q37025981-33F04421-BCCD-48C6-84E7-DF2D2B0E2F64 Q37150014-15A0EE75-7376-4CBC-BD94-0D2D36AE1729 Q37467263-785588EB-6ABE-4D9C-8102-790C0A749992 Q37467268-368F9C9E-555D-4264-AA2E-AF96A362F3A6 Q37991223-70E7C9AE-989B-401D-B4B9-1B71018F3D45 Q38018109-C59763ED-3D03-42B2-9B42-BC84468CBAB9 Q38134399-7E2B16B2-44A1-4F32-965D-C4B48ECEE397 Q38161274-30AA709B-C241-457B-BF89-A88534819225 Q38161964-44C12C94-135E-4BB8-B68E-AAF1F1FCAD21 Q38219435-534F78F0-254B-4B8E-9616-B34DD12FC3A4 Q38265982-09F44BBE-CE08-49F4-9A87-D0099A30A725 Q38404462-35BD7902-BB86-410D-9F86-D6D4A90B21E8 Q38457554-869FB05D-8ACB-4B5E-B3F3-1EDAEE73D735 Q38813874-A2E48221-4139-44BF-A82A-82804F2D3B8B Q38964974-44F1ACE4-CBE6-40A6-AB3F-48E46CACE1D0 Q39484798-96166786-F873-4418-8CEC-0854D34FBC0E Q39787455-8DC1A79A-DBB6-41E8-A70E-C77EB8706BAC Q40071286-D38F1E7D-76A5-4219-9FD1-BC743DAD3A2B Q41038941-5BD6F01B-618B-4CAB-A7AD-70674FF9F774 Q43811918-34AA9165-2524-431F-A28E-2A7DA1EAE32D Q44774546-9FC10EC9-8236-4095-89F1-66F34FDA004D Q48012912-7D347587-B140-4522-A8DF-BA38ED9058F5 Q48094451-2E190791-8234-4DB6-97B4-98F1441DA59C Q49101349-FE43E4B4-811E-4C0B-B405-A539A7934804 Q50094239-F0F22B9B-BE7C-4EC4-9E1B-46E99CD0980A Q50215292-AD9B07C4-ACDC-4302-B5A3-E1C24186B5BE Q50855561-CDF5D3E6-780B-4CE6-A4FB-92ECF5874876 Q51072279-2CC8E273-31DF-4662-AD02-D4DEDF9A087F Q52677126-A082ED3F-CFFA-4870-8DD7-46158F0D3E1D Q53087755-1022CEFD-3A93-4723-B697-7DC10CC56FC2 Q54354157-14605E87-FD35-41BA-B860-449BDAAAF78B Q55034870-AD322517-AFFE-4665-A5C6-FE18FDCAD85B

P2860

Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.

http://www.wikidata.org/entity/Q38489561

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Imatinib is effective in child ...... rench national phase IV trial.

@en

type

label

Imatinib is effective in child ...... rench national phase IV trial.

@en

prefLabel

Imatinib is effective in child ...... rench national phase IV trial.

@en

P1433

Q38489561-4DBE90E9-A1E4-4929-A95D-A1358EF394C1

P1476

Q38489561-813460A8-7684-43C7-BFFB-D33F71FC7F43

P2093

Q38489561-0891CB73-F6DD-48AE-9FE1-C74BDE5CE59A

Q38489561-1E2CF95D-9B1A-4BCC-8351-547932DAD130

Q38489561-222F19E8-F231-4FD8-BCE7-82FB0B42042E

Q38489561-264C1ADE-6B47-4D16-8ECF-6699502A6146

Q38489561-500DA44F-9DBC-4BD0-B2DC-43618755D521

Q38489561-55EE3344-15CA-4144-BF2B-02AB2FE094AA

Q38489561-6D6391BC-4AAD-4DDD-AAD7-4E1C566EF120

Q38489561-806E8812-B3D2-49F0-A0C1-251E7ED0FD13

Q38489561-8672DFE6-DADC-410E-9F15-9CBEB4C92B5E

Q38489561-9CC116B2-ABFE-4E6C-B47C-E04B5A01F7C4

P304

Q38489561-7F0806EA-C482-4201-A822-5A3EFD7B95E1

P31

Q38489561-A983BFDD-2673-4D13-85B8-DAD098AAA51E

P356

Q38489561-2DE1EEA9-61D6-4C48-8D45-B85B5E32AB5A

P407

Q38489561-B2CEA760-98F2-4B0A-ADEC-69BDA04D49D7

P433

Q38489561-29A26578-3825-40AA-897C-AF014D64A1FC

P478

Q38489561-687B6D72-E00A-4331-95F9-540AA9C50D9A

P577

Q38489561-459F51F2-2E58-40CB-87BC-ED22BE78A751

P698

Q38489561-8CD7C58A-B3E1-40CC-A142-E3CB8E1F3C76

P921

Q38489561-24858C45-0FDA-4934-A0FD-8E3E52DE5A26

Q38489561-D8088272-9729-4E83-9C4C-B5AFEB864F81

P356

JCO.2010.32.7114

P1433

Journal of Clinical Oncology

P1476

Imatinib is effective in child ...... rench national phase IV trial.

@en

P2093

André Baruchel

http://www.w3.org/2001/XMLSchema#string

Arnaud Petit

http://www.w3.org/2001/XMLSchema#string

Christian Berthou

http://www.w3.org/2001/XMLSchema#string

Christine Edan

http://www.w3.org/2001/XMLSchema#string

Claire Galambrun

http://www.w3.org/2001/XMLSchema#string

Cécile Vérité

http://www.w3.org/2001/XMLSchema#string

François Guilhot

http://www.w3.org/2001/XMLSchema#string

Françoise Mazingue

http://www.w3.org/2001/XMLSchema#string

Françoise Méchinaud

http://www.w3.org/2001/XMLSchema#string

Frédéric Bernard

http://www.w3.org/2001/XMLSchema#string

P304

2827-2832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.7114

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21670449

http://www.w3.org/2001/XMLSchema#string

P921

phase IV clinical trial